Blood Test for Lung Cancer
(PROACT-LUNG Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a blood test can detect lung cancer early. Researchers will collect blood samples from individuals at high risk of lung cancer who are undergoing a routine lung scan called LDCT (low-dose CT scan). The trial seeks participants aged 50 or older who have smoked heavily (20 pack-years or more) and are not currently receiving cancer treatment.
As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to earlier lung cancer detection.
What prior data suggests that this blood test is safe for early detection of lung cancer?
This study does not test any new treatments. Instead, it aims to confirm the accuracy of a blood test for early lung cancer detection. Since no new medicines or procedures are involved, there are no related safety concerns. Participants will only provide blood samples and undergo regular lung check-ups.
Why are researchers excited about this trial?
Researchers are excited about this trial because it focuses on developing a blood test for lung cancer, which could revolutionize early detection. Unlike traditional methods like CT scans or biopsies that are invasive or require advanced equipment, a blood test promises a simple, non-invasive approach. This could lead to earlier diagnosis and treatment, potentially improving survival rates and outcomes for patients with lung cancer.
What evidence suggests that this blood test is effective for early detection of lung cancer?
Research has shown that blood tests might help detect lung cancer early by identifying cancer-related substances in the blood. Some studies suggest these tests can find lung cancer markers even before symptoms appear. Early detection is crucial because it can improve treatment outcomes. Although limited information exists about this specific blood test, it could potentially complement current methods like CT scans to detect lung cancer sooner. Early results are promising, but further research is needed to determine the test's effectiveness.
Who Is on the Research Team?
Victoria Sumner
Principal Investigator
Freenome Holdings Inc.
Are You a Good Fit for This Trial?
This trial is for people aged 50 or older who are current or former smokers with a history of smoking at least 20 packs a year. Participants must understand and agree to sign consent forms.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Blood Sample Collection
Blood samples are collected from participants for the Freenome Multiomics Blood Test
Standard-of-Care Screening
Participants undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT)
Follow-up
Participants are monitored for safety and effectiveness after screening, with data collection on diagnostic tests and procedures related to lung cancer diagnosis
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Freenome Holdings Inc.
Lead Sponsor